Treating Chronic Pruritus: Are We at the Threshold of a Breakthrough?

• Published in: Skin (Milwood, N.Y.) Vol. 8; no. 4; pp. 1711 - 1713
• Main Authors: Smith, Payton, Kranyak, Allison, Johnson, Chandler E, Haran, Kathryn, Liao, Wilson, Bhutani, Tina, Koo, John
• Format: Journal Article
• Language: English
• Published: United States 01.07.2024
• ISSN: 2574-1624; 2574-1624
• DOI: 10.25251/skin.8.4.11

Chronic pruritis, characterized by persistent itchiness lasting more than six weeks, affects up to 15% of the population, significantly impairing quality of life. Despite its prevalence and impact, there is an absence of FDA-approved medications specifically for the treatment of chronic pruritus, highlighting a significant unmet need in dermatology. Advancements in dermatologic medications, however, including the development of biologics and Janus kinase (JAK) inhibitors, signal potential breakthroughs in pruritus management through a radically different mechanism of action that focuses on their effect on the nervous system. Currently, the most commonly utilized treatments for pruritis are sedating antihistamines, which have been largely ineffective for non-histamine-induced itch, underscoring the necessity for novel approaches. This editorial reviews key studies and clinical trials with a particular focus on cases of prurigo nodularis, where itch serves as the primary pathology rather than just a symptom. The effectiveness of dupilumab in phase III trials for treating prurigo nodularis, independent of its effects on dermatitis or atopic background, alongside the success of JAK inhibitors in managing chronic idiopathic pruritus, indicates a shift towards therapies that directly and specifically target itch nerve pathways instead of indirectly via immune system modulation or sedation. These developments suggest that significant progress may be on the horizon for treating chronic itch, providing hope for those suffering from pruritis, the number one cause of misery in dermatology.